Keros Therapeutics (NASDAQ:KROS) Director Buys $10,190.00 in Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Jean Jacques Bienaime bought 1,000 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was bought at an average cost of $10.19 per share, with a total value of $10,190.00. Following the transaction, the director directly owned 17,592 shares in the company, valued at approximately $179,262.48. The trade was a 6.03% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jean Jacques Bienaime also recently made the following trade(s):

• On Wednesday, April 15th, Jean Jacques Bienaime bought 1,000 shares of Keros Therapeutics stock. The stock was bought at an average cost of $11.70 per share, with a total value of $11,700.00.

Keros Therapeutics Stock Up 3.8%

Shares of KROS traded up $0.38 during midday trading on Wednesday, hitting $10.41. The company had a trading volume of 241,766 shares, compared to its average volume of 369,511. The company’s 50 day moving average price is $11.16 and its 200 day moving average price is $14.80. The stock has a market cap of $206.03 million, a price-to-earnings ratio of -3.46 and a beta of 0.94. Keros Therapeutics, Inc. has a 52 week low of $9.69 and a 52 week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.19). The company had revenue of $0.37 million during the quarter, compared to the consensus estimate of $1.93 million. Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%. Equities analysts anticipate that Keros Therapeutics, Inc. will post -5.19 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in shares of Keros Therapeutics by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,718,777 shares of the company’s stock valued at $43,011,000 after buying an additional 87,129 shares during the period. Western Standard LLC boosted its holdings in shares of Keros Therapeutics by 42.7% in the 3rd quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock valued at $34,644,000 after buying an additional 654,989 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Keros Therapeutics by 26.6% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 768,425 shares of the company’s stock valued at $15,645,000 after buying an additional 161,336 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Keros Therapeutics by 38.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock valued at $7,547,000 after buying an additional 205,022 shares during the period. Finally, Federated Hermes Inc. boosted its holdings in shares of Keros Therapeutics by 27.3% in the 4th quarter. Federated Hermes Inc. now owns 654,724 shares of the company’s stock valued at $13,330,000 after buying an additional 140,564 shares during the period. 71.56% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on KROS. Wall Street Zen downgraded shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Wells Fargo & Company dropped their target price on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Thursday, March 5th. Finally, Weiss Ratings downgraded shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 15th. Three equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $20.40.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.